|
Market Closed -
Nasdaq
16:00:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 22.01 USD | +0.59% |
|
+1.90% | -17.81% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 936M | |||||
| 1,047B | |||||
| 646B | - | - | - | ||
| 451B | |||||
| 355B | |||||
| 291B |
Select your edition
All financial news and data tailored to specific country editions
